Interim data from an ongoing Phase 2a clinical trial indicate that the investigational therapy MS1819-SD may provide therapeutic benefits for patients with cystic fibrosis (CF) who have exocrine pancreatic insufficiency (EPI), a digestive disorder. The trial (ACTRN12616000962437) is being conducted in patients with chronic pancreatitis (CP) who have EPI, but the drug is being…
The first study of cystic fibrosis (CF) patients who received antibiotics that caused inner ear disease or ototoxicity is enrolling participants, according to Sound Pharmaceuticals. The Phase 1b STOP Ototoxicity study (NCT02819856) is led by Dr. Patrick Flume, MD,…
ProQR Therapeutics says its investigational drug QR-010 improved respiratory symptoms in 70 adults with cystic fibrosis (CF) who participated in a Phase 1b trial of the inhaled therapy. Researchers saw the biggest improvements in patients with a lower lung function at the beginning of the study, which only targeted patients with…
The National Institutes of Health (NIH) has awarded Exotect a $224,576 Small Business Technology Transfer grant to develop small molecule therapies to treat cystic fibrosis and other diseases characterized by excessive airway mucous secretion. These include chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD) and asthma. Exotect, a preclinical early-stage Fannin Innovation…
Pro-ficiency has unveiled a new approach to educating and supporting U.S. cystic fibrosis (CF) patients and caregivers using its new platform, ProPatient. Pro-ficiency, based in Durham, North Carolina, provides online training technology for clinical trials. It platforms use real-world simulation scenarios to educate clinicians and physicians. ProPatient, which uses videos…
Vizient, which calls itself the nation’s “largest member-driven health care performance improvement company,” has awarded a contract for  Alcresta’s Relizorb — a product that helps with the digestion of healthy fats in serious diseases such as cystic fibrosis (CF). The Relizorb (immobized lipase) cartridge contains an enzyme that breaks down fats in tube…
Two months and 13,456 miles after TV and radio host Riki Rachtman committed to a solo motorcycle journey through all 48 contiguous states, the TV and radio host has completed his goal:, to raise funds for Claire’s Place Foundation, a nonprofit working with children and families touched by…
4D Molecular Therapeutics (4DMT) announced it has secured funding to complete studies necessary for its gene therapy candidate for cystic fibrosis (CF), 4D-710, to be tested in people. The therapy is composed of a what 4DMT describes as an advanced and customized adeno-associated virus (AAV) vector, which will carry…
The lunges keep coming for Lunges4Lungs, even as Mallory Smith recovers from the double lung transplant she has received to help extend her life. Friends of Smith started the transplant fundraising campaign, which involves people making donations for each of the leg-muscle exercises known as lunges that they perform. Although…
The U.S. Food and Drug Administration (FDA) granted orphan drug status to a broad spectrum antibiotic called iclaprim, developed by Motif Bio, for the treatment of one of the most common lung infections in patients with cystic fibrosis (CF), Staphylococcus aureus. The FDA’s designation could accelerate the availability of iclaprim for CF patients.
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.
